RT Journal Article
SR Electronic
T1 Physiological (TCR-like) regulated lentiviral vectors for the generation of improved CAR-T cells
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.17.21253300
DO 10.1101/2021.03.17.21253300
A1 Tristán-Manzano, María
A1 Maldonado-Pérez, Noelia
A1 Justicia-Lirio, Pedro
A1 Muñoz, Pilar
A1 Cortijo-Gutiérrez, Marina
A1 Pavlovic, Kristina
A1 Jiménez-Moreno, Rosario
A1 Nogueras, Sonia
A1 Carmona, MDolores
A1 Sánchez-Hernández, Sabina
A1 Aguilar-González, Araceli
A1 Castella, María
A1 Juan, Manel
A1 Marañón, Concepción
A1 Benabdellah, Karim
A1 Herrera, Concha
A1 Martin, Francisco
YR 2021
UL http://medrxiv.org/content/early/2021/03/20/2021.03.17.21253300.abstract
AB Background Chimeric antigen receptor (CAR) T cells directed against CD19 have achieved impressive outcomes for the treatment of relapsed/refractory B lineage lymphoid neoplasms. However, CAR-T therapy still has important limitations due to severe side effects and the lack of efficiency in 40-50% of the patients. Most CARs-T products are generated using retroviral vectors with strong promoters. However, high CAR expression levels can lead to tonic signalling, premature exhaustion and over-stimulation of CAR-T cells, reducing efficacy and increasing side effects. TCR-like expression of the CAR through genome editing resulted in enhanced anti-tumour potency, reducing tonic signalling and improving CAR-T phenotype. In this manuscript, we searched for LVs that mimic the TCR expression pattern as a closer-to-clinic alternative for the generation of improved CAR-T cells.Methods Different LVs containing viral and human promoters were analysed to select those that closely mimic a TCR-like kinetic profile upon T-cell activation. WAS gene proximal promoter-driven LVs (AW-LVs) were selected to express a second generation 4-1BB aCD19 CAR (ARI-0001) into T cells to generate AWARI CAR-T cells. TCR-like AWARI and EF1α-driven ARI CAR T cells were analysed for in vitro and in vivo killing efficiency using leukaemia and lymphoma cellular models. Tonic signalling, exhaustion markers and phenotype were determined by flow cytometry. Large-scale automated manufacturing of AWARI CAR-T cells was performed in a CliniMACs Prodigy bioreactor.Results Our data showed that LVs expressing the transgene through the WAS gene proximal promoter mimic very closely the TCR (CD3) expression pattern kinetic upon TCR stimulation or antigen encounter. Compared to EF1α-driven ARI CAR-T cells, AWARI CAR-T cells exhibited a higher proportion of naïve/stem cell memory T cells with less exhausted phenotype after efficient killing of CD19+ cells both in vitro and in vivo. AWARI CAR-T cells also showed lower tonic signalling and reduced secretion of pro-inflammatory cytokines and were efficiently manufactured in large-scale GMP-like conditions.Conclusions WAS-gene-promoter driven LVs can be used to generate physiological 4-1BB-CAR-T cell products with lower tonic signalling, improved phenotype and a safer profile. We propose the use of TCR-like LVs as an alternative to strong-promoter driven LVs for the generation of CAR-T products.Competing Interest StatementFMM, MTM, NMP, PM and KB are inventors of a patent for AW promoter for CAR-T cells applications. P.J.L is contractually associated to LentiStem Biotech, a Spin-Off company that has the license of that patent. The rest of the authors declare that the research was conducted in the absence of other commercial or financial relationships that could be construed as a potential conflict of interest.Funding StatementThis study was funded by the Spanish ISCIII Health Research Fund and the European Regional Development Fund (FEDER) through research grants PI12/01097, PI15/02015, PI18/00337 (F.M.) and PI18/00330 (K.B.); The CECEyU and CSyF of the Junta de Andalucia FEDER/European Cohesion Fund (FSE) for Andalusia provided the following research grants: 2016000073391-TRA, 2016000073332-TRA, PI-57069, PAIDI-Bio326, CARTPI-0001-201 (F.M.) and PI-0014-2016 (K.B); The Ministerio de Ciencia, Innovacion y Universidades (CDTI) to F.M. (00123009 / SNEO-20191072). K.B. and C.M held Nicolas Monardes contracts from regional Ministry of Health (#0006/2018 and C2-0002-2019 respectively). M.T.M., N.M.P and A.A.G. are funded by Spanish Ministry of Education and Science through fellowships FPU16/05467, FPU17/02268 and FPU17/04327 respectively. P.J.L is funded through an industrial doctorate MCI DIN2018-010180 to LentiStem Biotech. P.M is funded by Fundacion Andaluza Progreso y Salud. PM holds projects PI17/00672 (ISCIII) and PEER-0286-2019 (Consejeria de Salud-Junta de Andalucia). M.C.G is funded by Spanish Ministry of Education and Science through fellowship GJ (PEJ-2018-001760-A). MDC is funded by the grant PE-0223-2018CSyF of the Junta de Andalucia. MTM, NPM, PLJL, MCG, AGG are PhD students from the Biomedicine Programme of the University of Granada (Spain).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All donors from the Haematology Unit of Hospital Reina Sofia, Cordoba (Spain) gave their written informed consent and the study was performed according to the established guidelines of in the approved by the Regional Government Junta de Andalucia-Consejeria de Salud (date of approval: 22/02/2019, signed by Dra Cristina Lucia Davila Fajardo as secretary of the Research Ethics Committee), that comply with the requirements regarding quality and safety for donation, obtaining, storage, distribution, and preservation of human cells and tissues under the Spanish specific regulation (RD 9/2014) and International Conference of Good Clinical Practice. All the experiments involving animals were performed according to a protocol approved by the Institutional Animal Care and Use Committee of the University of Granada (13/12/2016/181) were in accordance with the European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes (CETS # 123) and the specific Spanish law (R.D. 53/2013). Subjects were randomly assigned to receive the different treatments and sample size estimation was calculated based on Mayer et al20.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data relevant to the study are included in the article or uploaded as online supplemental information.ATMPadvanced therapy medical productB-ALLB-acute lymphoblastic leukaemiaCARChimeric Antigen ReceptorCMVCytomegaloviruseGFPenhanced green fluorescent proteinEF1αElongation Factor 1-αEMAEuropean Medicine AgencyFDAFood and Drug administrationLVsLentiviral vectorsLTRlong-terminal repeatsMSCVmurine stem cells virusNTDnon-transduced cellsR/Rrelapsed/ refractoryScFvSingle chain variable fragmentSFFVSpleen focus forming virusTCRT cell receptorTCMT central memoryTEFT effectorsTEMT effectors memoryTN/SCMT naive/stem cell memoryTRACT cell receptor (TCR) constant alpha locusWASWiskott-Aldrich syndrome